Avenue Therapeutics, Inc. (ATXI)
OTCMKTS
· Delayed Price · Currency is USD
0.769
-0.031 (-3.88%)
At close: Dec 5, 2025
Avenue Therapeutics Employees
Avenue Therapeutics had 2 employees as of December 31, 2024. The number of employees decreased by 1 or -33.33% compared to the previous year.
Employees
2
Change (1Y)
-1
Growth (1Y)
-33.33%
Revenue / Employee
$702,000
Profits / Employee
-$1,872,000
Market Cap
2.45M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| CytoDyn | 13 |
| American Oncology Network | 1,914 |
| Northwest Biotherapeutics | 25 |
| Silence Therapeutics | 116 |
| Zomedica | 152 |
Avenue Therapeutics News
- 4 weeks ago - Avenue Therapeutics (ATXI) Sells Baergic Bio to Axsome Therapeutics - GuruFocus
- 4 weeks ago - Axsome Therapeutics acquires Baergic Bio from Avenue Therapeutics - Seeking Alpha
- 1 year ago - Avenue Therapeutics Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Maxim Group's 2024 Healthcare Virtual Summit - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights - GlobeNewsWire
- 1 year ago - Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference - GlobeNewsWire
- 1 year ago - Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy (Kennedy's Disease) - GlobeNewsWire